Evidence map›Paper›PMID 37919464›Full record

ArticleScientific reports2023

The effect of Ganoderma lucidum polysaccharide extract on sensitizing prostate cancer cells to flutamide and docetaxel: an in vitro study.

Ramin Rahimnia, Mohmammad Reza Akbari, Alimohammad Fakhr Yasseri, Diana Taheri, Akram Mirzaei, Helia Azodian Ghajar, Parmida Dehghanpoor Farashah, Leila Zareian Baghdadabad, Seyed Mohammad Kazem Aghamir

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Evaluation of Anticancer Potential ofAntioxidants (Basel, Switzerland) · 2025
    Article
  3. Potential Active Compounds ofFood science & nutrition · 2025
    Review
  4. Review
  5. International journal of molecular sciences · 2025
    Article
  6. Review
  7. A Phyto-mycotherapeutic Supplement, NamelyInternational journal of molecular sciences · 2024
    Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Ramin RahimniaDepartment of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Mohmammad Reza AkbariWomen's College Research Institute, Women's College Hospital, University of Toronto, Toronto, Canada.
Alimohammad Fakhr YasseriAlborz University of Medical Sciences, Shariati Hospital, Alborz, Iran.
Diana TaheriIsfahan Kidney Disease Research Center, Department of Pathology, Isfahan University of Medical Sciences, Isfahan, Iran.
Akram MirzaeiUrology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Helia Azodian GhajarUrology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Parmida Dehghanpoor FarashahUrology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Leila Zareian BaghdadabadUrology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Seyed Mohammad Kazem AghamirUrology Research Center, Tehran University of Medical Sciences, Tehran, Iran. mkaghamir@tums.ac.ir.
Tehran University of Medical Sciences · IRIsfahan University of Medical Sciences · IRShariati Hospital · IRUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ganoderma lucidum polysaccharide is the most widely used complementary therapy in cancer. The present study aims to investigate the possible interaction between Ganoderma lucidum polysaccharide and Docetaxel (a chemotherapy drug) and the first-line medication for prostate cancer treatment (Flutamide) and sensitizing the cells to these treatments. The cytotoxic effects of Ganoderma lucidum polysaccharide in combination with Docetaxel and Flutamide on prostate cancer cells were investigated by the MTT test, Hoechst staining, and flow cytometry. In addition, the expression of genes related to apoptosis, angiogenesis, Epithelial-Mesenchymal Transition pathway (EMT), and prostate cancer biomarkers by Real-Time PCR was investigated. The results demonstrated that IC50 values for Ganoderma lucidum polysaccharide (30 μM and 20 μM), Docetaxel (10 μM and 5 μM), and Flutamide (20 μM and 12 μM) with MTT were confirmed by flow cytometry in a dose and time-dependent manner. Regarding the high efficacy of Ganoderma lucidum polysaccharide in combination with Flutamide and Docetaxel, 10 μM and 5 μM Flutamide were used instead of 20 μM and 12 μM and 5 μM and 2 μM Docetaxel was used instead of 10 μM and 5 μM in PC3 and LNCap, respectively. Moreover, for the first time, it was shown that Ganoderma lucidum polysaccharide alone and in combination with Docetaxel and Flutamide significantly augmented apoptosis, reduced cell migration and colonization, and downregulated expression of KLK2 and EMT pathway genes in both PC3 and LNCap cell line (P < 0.01). Ganoderma lucidum polysaccharide synergistically increased the effect of Docetaxel and Flutamide and increased the sensitivity of the prostate cancer cell lines to these drugs. Therefore, it may provide a new therapeutic strategy against prostate cancer.

Indexed as

Prostatic NeoplasmsReishiCell Line, TumorDocetaxelFlutamideHumansMalePolysaccharidesProstateDocetaxelFlutamidePolysaccharides

Identifiers

PMID37919464
PMCPMC10622576
OpenAlexW4388219508

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.